Research map: Dual SGLT1/2 inhibition with sotagliflozin improves cardiac function and metabolism in type 2 diabetic mice

Back to the article

Papers in this map

  1. A Novel Paradigm for Heart Failure With Preserved Ejection Fraction · Walter J. Paulus · 2013 · 3564 citations · Cited by this paper
  2. AQP7 deficiency drives adipose tissue remodeling and disrupts homeostasis · 2025 · Related
  3. Diabetic Cardiomyopathy · Guanghong Jia · 2018 · 1876 citations · Cited by this paper
  4. 1,1-Diethoxyethane increases insulin sensitivity and ameliorates obesity and dyslipidemia in mice fed high-fat diet · 2026 · Related
  5. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure · Deepak L. Bhatt · 2020 · 1873 citations · Cited by this paper
  6. Risk stratification at prediabetes onset and association with diabetes outcomes using EHR data · 2025 · Related
  7. Diabetic Cardiomyopathy Revisited · Sihem Boudina · 2007 · 1552 citations · Cited by this paper
  8. GLP-1 receptor agonism results in reduction in hepatic ethanol metabolism · 2025 · Related
  9. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review · Subodh Verma · 2018 · 1002 citations · Cited by this paper
  10. Beta 2 adrenergic receptor agonists as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) · 2026 · Related
  11. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors · Gary D. Lopaschuk · 2020 · 908 citations · Cited by this paper
  12. Adolescence as a key developmental window for nutrition promotion and cardiometabolic disease prevention · 2025 · Related
  13. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production · Aurora Merovci · 2014 · 795 citations · Cited by this paper
  14. An IL6 variant -174 G-C alters cardiac hypertrophy but not cardiometabolic responses to HFD in mice · 2026 · Related
  15. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction · Carlos G. Santos‐Gallego · 2020 · 548 citations · Cited by this paper
  16. Quantitative Analysis of the Whole-Body Metabolic Fate of Branched-Chain Amino Acids · Michael D. Neinast · 2018 · 518 citations · Cited by this paper
  17. Leptin- and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes · Bingxuan Wang · 2014 · 513 citations · Cited by this paper
  18. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors · Teresa Salvatore · 2022 · 260 citations · Cited by this paper
  19. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states · S. Banerjee · 2009 · 221 citations · Cited by this paper
  20. Branched Chain Amino Acids in Metabolic Disease · Zoltan Pierre Arany · 2018 · 181 citations · Cited by this paper
  21. Coordinated Modulation of Energy Metabolism and Inflammation by Branched-Chain Amino Acids and Fatty Acids · Zhenhong Ye · 2020 · 181 citations · Cited by this paper
  22. Intracellular Na + Concentration ([Na + ] i ) Is Elevated in Diabetic Hearts Due to Enhanced Na + –Glucose Cotransport · Rebekah Lambert · 2015 · 116 citations · Cited by this paper
  23. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models · Ioanna Andreadou · 2020 · 97 citations · Cited by this paper
  24. SGLT2 Inhibitors and Ketone Metabolism in Heart Failure · Huitzilihuitl Saucedo‐Orozco · 2022 · 94 citations · Cited by this paper
  25. SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial · Katrine Meyer Lauritsen · 2020 · 67 citations · Cited by this paper
  26. Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study · Desiree Abdurrachim · 2018 · 66 citations · Cited by this paper
  27. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure · Robert Pietschner · 2021 · 66 citations · Cited by this paper
  28. Redefining Diabetic Cardiomyopathy: Perturbations in Substrate Metabolism at the Heart of Its Pathology · Lisa C. Heather · 2024 · 57 citations · Cited by this paper
  29. Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets · Mathias Mericskay · 2025 · 55 citations · Cited by this paper
  30. Mechano-energetic uncoupling in heart failure · Dunja Aksentijević · 2025 · 49 citations · Cited by this paper
  31. Impact of reduced uterine perfusion pressure model of preeclampsia on metabolism of placenta, maternal and fetal hearts · Lana McClements · 2022 · 42 citations · Cited by this paper
  32. New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans · Laura Ferté · 2021 · 35 citations · Cited by this paper
  33. SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach · Patrick McLean · 2025 · 33 citations · Cited by this paper
  34. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study · Maximilian Georg Posch · 2022 · 32 citations · Cited by this paper
  35. Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions · Adriana C. C. Girardi · 2024 · 31 citations · Cited by this paper
  36. Senescence and Type 2 Diabetic Cardiomyopathy: How Young Can You Die of Old Age? · Siân M. Henson · 2021 · 24 citations · Cited by this paper
  37. Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload · Sophia L. Young · 2021 · 22 citations · Cited by this paper
  38. Branched-chain amino acids alter cellular redox to induce lipid oxidation and reduce de novo lipogenesis in the liver · Chaitra Surugihalli · 2023 · 17 citations · Cited by this paper
  39. Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats · Peng Zhong · 2023 · 15 citations · Cited by this paper

Source: OpenAlex (CC0)